Heterologous antisera specific for murine T-cell antigen-recognition molecules were prepared by immunization of rabbits with dinitrophenyl-specific murine T-cell suppressor factors that had been purified by hapten-affinity chromatography. The antisera (i) bind to antigen-specific T-cell products that differ in their antigen-recognizing specificity; (ii) absorb the specific suppressor activity in preparations containing suppressor factors; (iii) stain all Lyt2+ T cells brightly in indirect immunofluorescence examination, stain some Lyt1+ cells (with low intensity), and do not stain B cells; (iv) precipitate cell membrane proteins from T cells that bear striking structural resemblance to the antigen-specific molecules used for immunization. These results suggest that, like B cells, there is a commonality between antigen-specific effector molecules released by T cells and their membrane-associated receptors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC349049 | PMC |
http://dx.doi.org/10.1073/pnas.78.10.6411 | DOI Listing |
Vaccine X
January 2025
Finlay Vaccine Institute, Av. 21 #19810, Atabey, Playa, Havana 11600, Cuba.
Background: The heterologous three-dose schedule of the protein subunit anti-COVID-19 SOBERANA®02 and SOBERANA® Plus vaccines has proved its safety, immunogenicity and efficacy in pediatric population, but durability of immunogenicity is not yet dilucidated. This study reports the safety and durability of the humoral and cellular responses in children and adolescents 5-7 months after receiving the heterologous vaccine schedule of SOBERANA® 02 and SOBERANA® Plus.
Methods: Children participating in a phase I/II clinical trial were followed-up for 5-7 months after the last dose.
Front Immunol
December 2024
Department of Blood Transfusion, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
The spread of multidrug-resistant strains of poses a great challenge in gonorrhea treatment. At present, vaccination is the best strategy for gonorrhea control. However, given the extensive antigenic variability of , the effectiveness of monovalent vaccines is limited.
View Article and Find Full Text PDFVaccine
January 2025
Laboratório de Bacteriologia, Instituto Butantan, São Paulo, SP, Brazil. Electronic address:
Diseases caused by Streptococcus pneumoniae (pneumococcus) produce a great impact on public health, killing about one million people annually despite available vaccines. Recent research has revealed that the pneumococcus produces extracellular vesicles (pEVs), which display selective cargo and hold potential for vaccine development. Here, we evaluated the immunogenicity and protective potential of pEVs derived from a non-encapsulated pneumococcal strain (R6) using murine models of pneumococcal colonization and invasive pneumonia.
View Article and Find Full Text PDFVirol J
November 2024
Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC) Lengshuitan District, Yongzhou City, 425000, Hunan, China.
The Hepatitis B core antigen (HBcAg) has been used as a carrier of several heterologous protein fragments based on its capacity to form virus-like particles (VLPs) and to activate innate and adaptive immune responses. In the present work, two chimeric proteins were designed as potential pancorona vaccine candidates, comprising the N- or C- terminal domain of SARS-CoV-2 nucleocapsid (N) protein fused to HBcAg. The recombinant proteins, obtained in E.
View Article and Find Full Text PDFFront Microbiol
November 2024
School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!